AAV packaging (research-grade)

Adeno-associated virus (AAV) is a  non-pathogenic single-stranded DNA virus. As one of the most important tools for gene therapy, recombinant adeno-associated virus (rAAV) can carry GOI to a variety of dividing and non-dividing cells showing long-term gene expression with low cellular immune response. Beside, the differences in capsid structure mediate the interaction of the AAV serotypes with different host cell receptors, leading to alternative tissue tropisms, which shows a great prospect in gene therapy research. In recent years, the FDA has approved numerous gene therapies delivered by rAAV, showing no serious vector-related adverse effects.

AAV Packaging Services

Our Superiority

Speed: PackGene’s proprietary technology on rAAV packaging is the major reason for our high quality and processing speed. We are committed to deliver requested amount of AAVs in the highest quality within 12-15 business days (If only the genes expressed in rAAV vector do not affect the AAV production too much), or we will give 5% of delayed order sum as credit which can used for the future orders.

Quality:The AAV genome copies is quantified via SYBR qPCR with ATCC Ref AAV for titer calibration, and the purity is determined by Coomassie-Blue staining. We deliver Guaranteed quantity of AAV, and in most case more than that, since we produce excessive scales to keep the Guaranteed promise. Besides, we also guarantee the endotoxin level of the AAV preps lower than 10 EU/ml.

Price for AAV packaging services

*The indicated titers are guaranteed except when the insert exceeds the packaging capacity (4.7 kb) or if you choose to provide us with your own modified rep/cap plasmid or helper plasmid.

Notice: If AAV serotypes you desire for package are currently under patents, and your application is for commercial use or clinical trials. We advise that you contact the patent owner to obtain authorization beforehand.

AAV In Vivo Delivery & Experiment Design

 For target tissues with few references, it is recommended that researchers determine the most ideal serotype through pre-experimental tests, which will also be one of the heat innovations. 

Pre-experimental design can be conducted as below:

1.Serotype Selection: If you are not sure which AAV serotype is most suitable for your study, you can try more than three different fluorescent AAV serotypes for a pre-infection experiment.

2. Gradient Dilution Infection: Due to the length and expression differences of each gene, it is strongly recommended to conduct gradient test of 3-4 injection doses of AAV expressing the target gene before the formal experiment, and increase by 3 times in turn according to the minimum requirements (e.g., 1E+11GC, 3E+11GC, 9E+11GC in gradient dilutions).

3.Experimental Control: Set a GFP positive control with the same serum type and the same promoter.

4.Detection Time: Usually the expression can be detected 3~4 weeks after injection, and it is recommended to do it after 4 weeks or more.

AAV in vitro infection

• For cells cultured in vitro, AAV-DJ and AAV6 are common choices. AAV-DJ can infect more than 80% of cells under conventional culture, and AAV6 has the strongest ability to infect blood-derived cells.
• It is strongly recommended that the gradient infection test (at least 3-4 gradient dilutions, such as MOI=1×10^3,MOI=1×10^4,MOI=1×10^5, and MOI=1×10^6) should be performed for the first use of AAVs and no cytotoxicity is a basic requirement for this kind of experiments.
• Detection Time: Usually 2-7 days after infection.

Fast Service Ordering

• 

  Brochure-Helping Gene Therapy